JACOBIO-B (01167) announced its 2025 financial results, reporting revenue of approximately 53.5 million yuan. Research and development expenses decreased by 42.9% year-on-year to 1.886 billion yuan, while administrative expenses fell by 20.2% to 344 million yuan. The net loss narrowed by 6.25% compared to the previous year, reaching about 146 million yuan. The company possesses a robust patent portfolio that safeguards its drug candidates and technologies. As of December 31, 2025, the company held 380 valid patents or patent applications filed globally, with 146 patents already granted or allowed in key international markets. During the year, the company entered into a licensing and collaboration agreement with AstraZeneca AB to jointly develop and commercialize the pan-KRAS inhibitor JAB-23E73. Under the terms of this agreement, Beijing Jacobio is entitled to receive an upfront payment of $100 million from AstraZeneca and is eligible for additional milestone payments upon achieving specific development, regulatory, and commercial milestones, with a total potential value of up to $1.915 billion. Furthermore, if the licensed product is successfully commercialized, Beijing Jacobio will be entitled to receive tiered royalties based on the net sales of the product.